Printer Friendly

Eisai, Nitto Denko to Co-develop Transdermal Formulation of Alzheimer's Disease Agent ARICEPT.

Tokyo, Japan, May 11, 2006 - (JCN) - Eisai announced on May 10 that it has signed a joint research agreement with Nitto Denko.

Under the agreement terms, the two companies will collaborate in developing a transdermal formulation (adhesive tape) of ARICEPT, an agent for treating Alzheimer's disease.

Nitto Denko, a Japanese leading liquid-crystal film manufacturer, has established various methods for drug formulation design. In particular, the company retains expertise in synthesizing adhesive materials suitable for controlled release.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:May 11, 2006
Words:86
Previous Article:Novartis Pharma, Chugai Pharmaceutical to Ship Agent for Postmenopausal Breast Cancer.
Next Article:AnGes MG Announces Results of Phase I Clinical Trial of HGF Gene Medicine.


Related Articles
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease.
Eisai Files Application Seeking Additional Indication for ARICEPT in US.
Eisai Resubmits Supplemental New Drug Application for Aricept, Alzheimers Disease Drug, to FDA.
Eisai Announces Results of Overseas Clinical Trials of Donepezil in Treating Vascular Dementia.
Asahi Kasei Pharma and Eisai in Sales Promotion Agreement for Eril in China.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Eisai Files Application Seeking Additional Indication for ARICEPT in Europe.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Nitto Denko Subsidiary Develops Novel Drug Delivery Technology Platform; Higher Drug Efficacy with Less Side Effects Expected.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |